AstraZeneca (AZN.US) quarterly profits exceed expectations, maintains full-year performance guidance amid tariff impact.

According to the Securities Times APP, AstraZeneca (AZN.US) announced that its first quarter profit for 2025 exceeded expectations and reiterated its full-year performance guidance. The financial report shows that AstraZeneca's total revenue for the first quarter was $13.59 billion, lower than market expectations; core earnings per share were $2.49, a 21% year-on-year increase, exceeding analyst expectations.